A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2018-08-14
Target enrollment:
Participant gender:
Summary
Two forms of insulin lispro (LY900014 and Humalog®) and two forms of insulin aspart
(NovoRapid® and Fiasp®) will be given to trial participants with diabetes mellitus type 1 by
injection under the skin. The study will assess how fast the active ingredient (insulin
lispro or insulin aspart) gets into the blood stream and how long it takes the body to remove
it. A test meal will be given to trial participants to assess the course of the blood sugar
lowering effect of the investigational products. The safety and tolerability of LY900014 will
also be assessed. Screening is required within 14 days prior to the lead in. For each
participant, the study will last up to 91 days.